MedTrace Logo

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

NCT04405674 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-11-22

No results posted yet for this study

Summary

A phase II, open-label, multicenter, two cohorts, prospective clinical study to investigate the efficacy and safety of tislelizumab (anti-pd1 antibody) combined with chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer patients with EGFR sensitizing mutation who failed EGFR TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) therapy.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle

DRUG

Carboplatin

Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles

DRUG

Pemetrexed

Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

DRUG

Bevacizumab

Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle

DRUG

Nab paclitaxel

Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2022-04-30
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405674 on ClinicalTrials.gov